Novartis AG Environmental Analytics
Environmental and financial analysis dashboard for Novartis AG. Industry: MANUFACTURING
Company Overview for Novartis AG
Highlights
Showing data for FY2023
Operational Environmental Cost
$70m
Operational Environmental Cost Intensity
0.14%
Total Environmental Cost
$1,181m
Total Environmental Cost Intensity
2.38%
ΔOperational Environmental Cost (2020-2023)
$-65m
Decoupling Rate (2020-2023)
18%
Adjusted EBITDA
$19,385m
Adjusted EBITDA Margin
39%
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 0.64% | 7.04% | -24.19% | ||
| 0.14% | 0.14% | 0.15% | 0.12% | |
| -5.88% | -42.43% | -66.25% | ||
| 0.12% | 0.11% | 0.06% | 0.02% | |
| $136m | $132m | $112m | $70m | |
| -2.43% | -15.39% | -37.17% | ||
| 0.26% | 0.25% | 0.21% | 0.14% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| 8.83% | 18.63% | -37.74% | ||
| 2.62% | 2.83% | 3.35% | 2.23% | |
| 7.82% | 15.88% | -37.70% | ||
| 2.88% | 3.08% | 3.56% | 2.38% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
39%
Adjusted EBIT Margin
21%
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$52,691m | $53,089m | $53,293m | $49,729m | |
| 0.76% | 0.39% | -6.69% | ||
$34,516m | $15,767m | $35,290m | $30,273m | |
| 65.51% | 29.70% | 66.22% | 60.88% | |
$18,174m | $37,322m | $18,004m | $19,456m | |
| 34.49% | 70.30% | 33.78% | 39.12% | |
$11,348m | $30,565m | $9,782m | $10,634m | |
| 21.54% | 57.57% | 18.35% | 21.38% | |
| ENVIRONMENTAL COST DATA | ||||
$136m | $132m | $112m | $70m | |
| 0.26% | 0.25% | 0.21% | 0.14% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
$18,039m | $37,189m | $17,892m | $19,385m | |
| 34.23% | 70.05% | 33.57% | 38.98% | |
$11,213m | $30,432m | $9,670m | $10,564m | |
| 21.28% | 57.32% | 18.14% | 21.24% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
0.12%
Scope 2 (% of Sales)
0.02%
Operational Environmental Cost Intensity
0.14%
Scope 3 (% of Sales)
2.23%
Total Environmental Cost Intensity
2.38%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Novartis AG | CH | $70m | 0.14% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $1,368m | 54.66% | N/A | N/A |
Energy-related activities (3) | $48m | 1.93% | N/A | N/A |
Upstream transportation (4) | $271m | 10.83% | N/A | N/A |
Waste (5) | $31m | 1.23% | N/A | N/A |
Business travel (6) | $19m | 0.77% | N/A | N/A |
Commuting (7) | $3m | 0.13% | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $232m | 9.25% | N/A | N/A |
Processing of products (10) | $1m | 0.03% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $530m | 21.16% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $2,504m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023